AzTrials
AzTrials

Pulmonary Disease, Chronic ObstructiveNCT02853383

Registry of COPD Patients From Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow

An observational study of Pulmonary Disease, Chronic Obstructive, run by Interregional Public Organization, Russian Respiratory Society at 1 site in Russia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To describe the clinical profile of COPD patient who is under outpatient surveillance at polyclinic institutions of Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade, distribution by disease phenotype, disease exacerbation rate in the… Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Pulmonary Disease, Chronic Obstructive
How many people
2,000 participants
Where
1 siteRussia
Study dates
Dec 2016to Feb 2019
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Randomly selected polyclinic institutions of Moscow will take part in the study and enrol into the registry 2000 patients for representativeness of sample for analysis of COPD prevalence in Moscow. The patient population includes male and female patients over 40 years of age, smokers or ex-smokers, under outpatient surveillance at polyclinic institutions of Moscow with diagnosis codes according to ICD J40 - J44 and diagnosed COPD, as confirmed by spirometry results

Who may be able to join

  • smokers or ex-smokers, with previously diagnosed COPD
  • COPD diagnosis corresponding to ICD codes J40 - J44 (J40 - Bronchitis, not specified as acute or chronic, J41 - Simple and mucopurulent chronic bronchitis, J41.0 - Simple chronic bronchitis, J41.8 - Mixed simple and mucopurulent chronic bronchitis, J 42 - Unspecified chronic bronchitis, J 43 - Emphysema, J 44 - Other chronic obstructive pulmonary disease
  • COPD diagnosis confirmed by spirometry results (spirometry is performed as normal with bronchodilator testing using salbutamol 400 µg, post-BD FEV1\ FVC < 0.7)

Who cannot join

  • Tuberculosis
  • Sarcoidosis

Trial locations and contacts

1 site in 1 country.

Olga N Brodskaya, M.D., Ph.D. contact

+79166145695

rropulmo@mail.ru

Natalia U Kravchenko, M.D. contact

+79161183219

pulmokongress@mail.ru

Russia1 site, 1 recruiting
  • Russian respiratory Society

    Moscow, 105077

    Olga N Brodskaya, M.D., Ph.D, +79166145696, rropulmo@mail.ru

    Recruiting

Other trials in Russia

About this study

Official title: Registry of COPD Patients Who Undergo Outpatient Treatment or Are Under Surveillance at Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow

To describe the clinical profile of COPD patient who is under outpatient surveillance at polyclinic institutions of Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade, distribution by disease phenotype, disease exacerbation rate in the setting of real-life clinical practice).

Read the detailed description

The registry of COPD patients in fact represents non-interventional multicenter retrospective study including all COPD patients included into the registry retrospectively from patients medical records and newly diagnosed under outpatient surveillance at the selected polyclinic institutions of Moscow.

The registry will include all patients with registered diagnoses J40 - J44 according to ICD-10 with spirometry results confirming COPD diagnosis, who are at the study start under outpatient surveillance, and also newly registered patients diagnosed with COPD (ICD-10 J40 - J44, as confirmed by spirometry results) during the conduction of the registry program at the selected polyclinic institutions of Moscow (according to ICD: J40 - Bronchitis, not specified as acute or chronic, J41 - Simple and mucopurulent chronic bronchitis, J41.0 - Simple chronic bronchitis, J41.8 - Mixed simple and mucopurulent chronic bronchitis, J 42 - Unspecified chronic bronchitis, J 43 - Emphysema, J 44 - Other chronic obstructive pulmonary disease) based on regular (yearly) retrospective analysis of patient records with data entry into a consolidated database.

It is planned to enrol into the study approximately 2000 male and female patients over 40 years of age with diagnosed COPD (as confirmed by spirometry results).

The present observational multicenter descriptive study will be conducted in the setting of routine clinical practice of outpatient polyclinic institutions. There is no hypothesis to be tested in this study.

The study will be conducted in outpatient polyclinic institutions of the primary medical care system of Moscow. Pulmonologists of the primary medical care system will be engaged as investigators. These are the physicians, whom the patients with tentative COPD diagnosis are referred to in the Russian Federation and who within the scope of their responsibilities have access to source medical records and who evaluate the quality of diagnosis and extent of treatment prescribed to COPD patients.

The present study is observational therefore it does not require a treatment regimen or directions for patient management. The patients receive medical care in line with routine practice for treatment of this disease in the Russian Federation. Patient participation in the study should not in any way affect the principles and extent of treatment received by the patient according to routine clinical practice.

Physicians-investigators will enter into the study the information (data) concerning COPD patients, both those already registered at the selected medical treatment and preventive care institution, and newly registered patients as they seek attention at the outpatient polyclinic institutions.

The main purpose of the present study consists in collection of data concerning COPD patients who under surveillance at outpatient polyclinic institutions of Moscow using patient medical records and their medical history. This protocol does not specify any obligatory visits or examinations.

Patient data will be entered into the registry de-identified. The patients will be identified by their screening number and initials. Then the Physician-investigator will evaluate patient compliance with inclusion criteria. The study will enrol patients meeting all the inclusion criteria and not having any of the exclusion criteria.

Only the physician who enters patient data into the regional COPD registry possesses patient contact information, and henceforth only this physician will enter de-identified patient data according to study design. This physician does not influence the choice of examination extent, treatment strategy and medication.

Keywords
Chronic Obstructive Pulmonary Diseases, COPD
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. COPD prevalence among patients registered in the healthcare system of Moscow (under outpatient surveillance at polyclinic institutions of Moscow).

    COPD prevalence among patients registered in the healthcare system of Moscow (under outpatient surveillance at polyclinic institutions of Moscow).

    Measured: 1 day

  2. To describe the clinical profile of COPD patient in Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade

    To describe the clinical profile of COPD patient who is under outpatient surveillance at polyclinic institutions of Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade, distribution by disease phenotype, disease exacerbation rate in the setting of real-life clinical practice).

    Measured: 1 day

Secondary outcomes (12)
  1. Percentage of patients with different disease phenotypes among outpatients

    Characterize percentage (%) of COPD patients wth different disease phenotypes among outpatients

    Measured: 1 day

  2. Percentage of prescriptions of medicinal products to COPD patients depending on disease severity grade in the setting of real-life clinical practice

    Percentage of prescriptions of medicinal products to COPD patients depending on disease severity grade in the setting of real-life clinical practice

    Measured: 1 year

  3. Distribution (%) of COPD patients who seek attention from primary medical care physicians by severity of airway obstruction

    Distribution (%) of COPD patients who seek attention from primary medical care physicians by severity of airway obstruction

    Measured: 1 year

  4. Mean number of exacerbations requiring medical attention (outpatient prescription of oral corticosteroids and/or antibiotics) in the last year in COPD patients

    Mean number of exacerbations requiring medical attention (outpatient prescription of oral corticosteroids and/or antibiotics) in the last year in COPD patients

    Measured: 1 year

  5. Mean number of hospitalizations in the last year in COPD patients

    Mean number of hospitalizations in the last year in COPD patients

    Measured: 1 year

  6. Disease burden based on the collected data concerning the duration of temporary disability

    Disease burden based on the collected data concerning the duration of temporary disability in days

    Measured: 1 year

  7. Disease burden based on the collected data concerning the outpatient visits due to COPD

    Disease burden based on the collected data concerning the outpatient visits due to COPD in last year

    Measured: 1 year

  8. To determine the percentage of patients with eosinophilic inflammation according to haematology results

    To determine the percentage of patients with eosinophilic inflammation according to haematology results

    Measured: 3 years

  9. To describe treatment regimens prescribed to COPD patients depending on disease severity grade in the setting of real-life clinical practice

    To describe treatment regimens prescribed to COPD patients depending on disease severity grade in the setting of real-life clinical practice

    Measured: 3 years

  10. To establish the percentage of medical prescriptions for treatment of COPD patients which comply with current Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease.

    To establish the percentage of medical prescriptions for treatment of COPD patients which comply with current Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease.

    Measured: 1year

  11. To evaluate the disease burden based on the collected data concerning the duration of temporary disability of patients under outpatient surveillance

    To evaluate the disease burden based on the collected data concerning the duration of temporary disability of patients under outpatient surveillance

    Measured: 1 year

  12. To evaluate the disease burden based on the collected data concerning the number of hospitalizations due to COPD exacerbations

    To evaluate the disease burden based on the collected data concerning the number of hospitalizations due to COPD exacerbations in last year

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2016 (estimated)
  2. Study startDec 2016
  3. Primary completionJan 2019
  4. Study completionFeb 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
2,000 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT02853383
Sponsor's protocol ID
RRS-001
Status last verified
Feb 2019
First submitted
14 Jul 2016
Last updated
4 Feb 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Disease, Chronic Obstructive, run by Interregional Public Organization, Russian Respiratory Society at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Olga N Brodskaya, M.D., Ph.D. (+79166145695, rropulmo@mail.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

COPD prevalence among patients registered in the healthcare system of Moscow (under outpatient surveillance at polyclinic institutions of Moscow). (time frame: 1 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in